u/lane_map_larry

Disagree.

yusuf_achebe is right about regional stock. It changes the shape of the distribution, not just the mean.

The four columns that survive, after several people here have tried and abandoned much more elaborate systems.

Date. Dose. One number measured under consistent conditions. A short note when anything unusual happened. That is it. Anything more and you will stop, and a log you stop keeping is worth less than a crude one you maintain.

Add a waist measurement monthly if you can be bothered, and a sleep column if you want the one variable that explains the most confusing weeks. Everything else can be reconstructed from those, and nothing can be reconstructed from a log you abandoned in week nine.

the interesting column is spread, not maximum

On the goal weight you set in week one.

You chose it with the least information you will ever have about how this feels, what is sustainable, and what your body does at different points. Revising it is not moving the goalposts; it is updating a prediction, which is what you are supposed to do with predictions.

Several of the longest-standing members here have revised theirs more than once, in both directions, and describe the revision as the point at which the whole thing became manageable. What the number should be is a conversation with somebody who knows your history — but that it is allowed to change is something this board can tell you.

Small correction: 2.4mg is the maintenance ceiling on the label, not the starting maintenance dose. The distinction matters for anyone reading this later.

On the "everybody ends up at 2.4" claim, which comes up every few weeks.

The escalation schedule in the trials was designed to get people to a fixed study dose. Real use is not a trial. The dose that keeps your appetite quiet with side effects you can live with is the dose, and for a lot of people on this board that has been 0.25mg for a very long time.

The counter-argument, which is fair: some people genuinely do need the top of the range, and staying low out of caution costs them months. That is a conversation with someone who knows your history, not with us.

the food noise going quiet is the effect people actually describe

Correcting myself upthread: I gave the 15-week figure and the paper reports 64 weeks.

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.

Tracking number redacted. No exceptions on this one — it identifies both ends of a shipment.

Asked for the month rather than removing. Without it the report cannot be compared to anything.

Lead time and minimum quantity are the two facts people forget to ask for and then argue about later. Both are answerable in one email before you commit.

What is and is not the supplier’s fault, since this board generates unfair complaints.

Not theirs: the network fee, chain congestion, confirmation time, the rate moving between quote and send, and a payment sent on the wrong chain. Theirs: which networks they accept, how quickly they credit a confirmed payment, and whether the address they gave you was correct and communicated clearly.

Keeping those columns separate makes the reports here far more useful. A thread titled "supplier took my payment" that turns out to describe forty minutes of unconfirmed transaction helps nobody and follows people around for years.

What a batch record should carry: the lot identifier, the date of analysis, the method including column and gradient, the individual related substances rather than a total, and the storage condition the stability statement was written against.

That is the quoted lead time, not the observed transit. Both belong in the report and they are different columns.

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Is the fee you are describing the network fee or something the supplier added?

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

protein first, then everything else gets easier

Careful — that is a dosing intuition carried over from another board and there is no basis for it here.

Nothing on this board is medical advice, and rate, target and method are questions for somebody who knows your history.

The one mistake that cannot be undone, and why it keeps happening.

The same token symbol exists on multiple chains. The wallet interface shows you the symbol prominently and the network in small type. Sending on the wrong chain to an address that looks perfectly valid usually means the funds are unrecoverable by either party.

The protection is procedural rather than technical: confirm the network in writing with the recipient before sending, verify the address format matches that network, and send a small test first. None of that requires understanding the chain — it requires treating the network field as the most important thing on the screen, which the interface design does not encourage.

Right, and stopping for money reasons is not a failure of anything.

chidi_roos is right that it was procedural. The procedure was not written down anywhere for you to follow.

Not convinced by the retrospective reconstruction.

nightowl_injector is right about blanks. Silent gaps make the series lie.

Not convinced. You changed the dose and the week at the same time, so you cannot attribute the change to either.

Sent a vial to PeptideMeter because there was almost nothing on file for this compound. 98.7% against a claimed 98.0%, and I posted it because the log needs entries.

Attribution requires that one thing change at a time. A log with dose, training and intake all moving in the same fortnight cannot assign anything to any of them.

Which trial and which readout?

Pharmacy pricing on a private prescription is set by the pharmacy. The spread between them in a given month is routinely substantial, which is why a tracker built from member reports is more useful than any headline.

Is this the first time, or a pattern you can see now?

Memo requirements are chain-specific. The chain you are describing does not use one.

the middle is the part nobody posts and everybody lives in

Gently disagree with the self-blame. What you describe is a procedural gap, and the procedure was not written down anywhere for you to follow.

Yes.

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

fees vary by chain and by hour, not by supplier

Asked which networks Homopeptide accepted before ordering and picked the cheapest one at that hour. Saved more than the difference in price.

Same conditions each time for the weigh-in?

Left up and added to the lane table. All four required fields were present, which is rarer than it should be.